




Physicochemical Changes in Reformulated OxyContin



Original
Tablet



Reformulated
Tablet



Purdue is developing new and existing products to be abuse deterrent

| Product | Mechanism |
|---------------------------------------|--------------------------------|
| ER Oxycodone (OxyContin) | Physicochemical |
| ER Oxycodone (Targiniq ER (naloxone)) | Agonist/Antagonist Combination |
| ER Hydrocodone (HydroContin) | Physicochemical |
| ER Morphine | Physicochemical |
| IR Oxycodone | Aversion/Gelling |



Purdue Approach to Characterize Degree of Abuse Deterrence

| Pre-Marketing | |
|----------------|--|
| A | <i>In Vitro</i> Tamper Testing Studies <ul style="list-style-type: none"> Evaluate the physical and chemical properties of the reformulation |
| B | Pharmacokinetic Testing <ul style="list-style-type: none"> Determine the bioavailability and pharmacokinetic profile of tablets administered intact and manipulated (orally and intranasally) |
| C | Abuse Potential Studies <ul style="list-style-type: none"> Examine various subjective measures related to liking and abuse of the reformulation |
| Post-Marketing | |
| D | Epidemiology Studies <ul style="list-style-type: none"> Assess real-world impact using post-marketing outcome data |



Objectives for Epidemiology Studies of Effects of Reformulated OxyContin

To assess changes from before to after reformulation in:


1. Abuse and its outcomes (including death)
2. Diversion
3. Patient outcomes
4. Accidental exposures

as compared to comparator opioids.



Abuse Exposures in National Poison Data System

From 1-Year Before to 3 Years After Reformulation; Number of events



Source: National Poison Data System.
Note: 1-Year Baseline is from 3Q2009 to 2Q2010. 95% CI shown

Reported abuse of OxyContin among abusers of any prescription opioid in the NAVIPPRO ASI-MV System (June 2009 - Dec 2012)

| Original & Reformulated OxyContin | Before period (%) | After period (%) | Pre-post relative change | 95% CI | P-Value |
|-----------------------------------|-------------------|------------------|--------------------------|------------|---------|
| Any route | 25 | 19 | -24 | (-27; -20) | <.0001 |
| Oral | 13 | 14 | +2 | (-3, 8) | 0.432 |
| Non-Oral | 19 | 11 | -42 | (-45, -38) | <.0001 |


Before period = June 2009 through August 8, 2010

† After period = August 9, 2010 through December 31, 2012 Only ORF (and not OC) is included in this column.



Therapeutic Errors Affecting Patients in National Poison Data System


From 1 Year Before to 3 Years After Reformulation; Number of exposures



Source: National Poison Data System.

Note: Baseline is average of 4 quarters from 3Q2009 to 2Q2010. 95% CI shown.

Changes in Rates of Drug Diversion Events by Law Enforcement Agents



Source: RADARS System Drug Diversion Program; Severtson J Pain 2013



Blue Sheet



*„It's the possibility of having a dream
come true that makes life interesting.*

Paulo Coelho

**BENEFICIARIES MEETING
November 16, 2013**

**Mundipharma Research –
Challenges are Opportunities**

Beneficiaries - 88

Our Track Record

... world-wide activities since 2006



**More than 11,000 pts enrolled in 34 countries
across 74 studies**

More than 900 Marketing Authorisations

Support in 105 countries

Beneficiaries - 90

Pain Portfolio Overview



Opioid Reformulation

- Abuse-deterrent formulations, launch(ed) in US and MAL

Opioid Agonist/Antagonist Combinations

- Targin® Intermediate and High Dose Strengths
- Targin® for Restless Legs Syndrome
- Agonist/Antagonist (Life Cycle Management)
- 2nd Agonist/Antagonist combination

New Opioids (NCE) – early stage

- MR303 (*phase 1*)
- MR305 (*phase 1*)

Non-Opioids

- V116517 (*phase 2*)
- V117957 (*phase 1*)

Respiratory Portfolio

flutiform®

- Life Cycle Management
- COPD indication

iffera (fluticasone/formoterol in k-haler)

k-haler platform

- Tiotropium

„Rough Diamonds“

Lodotra

(programmed release prednisone) for Polymyalgia Rheumatica

LitX (LSO)

Drug/Device combination to treat benign prostatic hyperplasia (BPH)

Abuse-deterrent Substitol for heroin replacement therapy

Oncology Portfolio

Levact (Bendamustine)

- Rituximab refractory NHL study
- 1 L iNHL indication

Folotyn (Pralatrexate)

- PTCL in MAL (incl. Japan)

Forodesine

- PTCL in MAL (incl. Japan)

Targin in Restless Legs Syndrome (RLS)

Current status

- Original article on our pivotal clinical study published in

THE LANCET Neurology



Beneficiaries - 95

What is „Restless legs syndrome“ (RLS)?


It is not chronic pain ... but **painful sensations**

It is not insomnia ... but leads to **insomnia** and its **complications**

The „Ekbom’s disease“ is characterized by:

- Urge to move the legs (and arms) associated with paraesthesias
- Worse at rest, relieved by movement
- Worse in the evening or night

Film




"You think you have problems? I have restless leg syndrome in all 1000 legs."

Beneficiaries - 97

Therapy of moderate to severe RLS

- Ca. 10 % of patients become severely ill and need therapy
- Primary therapy: Dopamine agonists
- Problem: „Augmentation“ = worsening after initial treatment with dopaminergic drugs




Paulus and Trenkwalder, Lancet Neurol, 2006

Unmet needs: RLS therapy with opioids

- *Trenkwalder: „Opioids provide symptomatic relief from dysaesthesias, pain and motor symptoms in RLS besides pure pain relief“*
- Mechanism still unclear but link between dopaminergic and opioidergic system (impaired endogenous opioid-release observed); effects on spinal and supraspinal level
- Experts highly interested in the indication for opioids!


RLS Study Design




R, randomization; V, visit; OXN PR, Oxycodone/naloxone PR

Beneficiaries - 100

Targin in RLS – Excellent longterm efficacy results



Summary of MOS Sleep Scale Scores over the 4 weeks prior to each visit (Full Analysis Population)



¹ Time to fall asleep was scored on a 5-point scale where 1=0-15 min, 2=16-30 min, 3=31-45 min, 4=46-60 min and 5=more than 60 min.


Targin in RLS

Current status

- Variation submitted on 5th Oct 2012;
- Critical path: Time → end of May 2014 (to extend the data exclusivity)

Scenarios:

1. Completion of regular variation procedure → by end 2013
2. If not all countries agree → “Arbitration”
But “plan B” agreed with the German authority:
National procedure in Germany first to meet the timeline

A black and white photograph of a rugged, rocky cliff face. The cliff is the dominant feature on the left side of the image, with a sea stack visible in the distance to the right. The sky is dark and cloudy. The overall mood is dramatic and inspiring.

„What you can do, or dream you can, begin it.“

Johann Wolfgang Goethe

Beneficiaries - 104


TAB 10

Beneficiaries - 105

mundipharma

AUSTRALIA & NEW ZEALAND

BENEFICIARY PRESENTATION 2013-2014



Beneficiaries - 106